CTT Pharma wins US patent for micelle-based nicotine, vitamin, caffeine delivery technology
CTTH•US patent expands delivery technology protection
CTT Pharmaceutical Holdings received a U.S. continuation-in-part patent covering micelle-based delivery for nicotine, vitamins, and caffeine.
The patent is set to issue Aug. 11, 2026, expanding protection for the company’s delivery technology.
The coverage supports multiple oral formats, including dissolvable strips, gum, and pouches.
